Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Construction method of acute T lymphocytic leukemia cytarabine drug-resistant cell strain

A technology of lymphocytes and drug-resistant cells, applied in the field of biomedicine, can solve problems such as myelosuppression, drug resistance, and central nervous system toxicity, and achieve the effect of improving the cure rate, great practical value, and improving long-term quality of life

Inactive Publication Date: 2020-09-15
THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, most chemotherapy regimens are based on high-dose Ara-C (HD-Ara-C), which has achieved good therapeutic effects, but long-term clinical application also leads to the occurrence of drug resistance, bone marrow suppression, central nervous system toxicity and Serious side effects such as digestive tract

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction method of acute T lymphocytic leukemia cytarabine drug-resistant cell strain
  • Construction method of acute T lymphocytic leukemia cytarabine drug-resistant cell strain
  • Construction method of acute T lymphocytic leukemia cytarabine drug-resistant cell strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043]S1: using the method of the present invention to construct Ara-c-induced human acute T lymphoblastic leukemia-resistant Ara-C cell Jurkat cell line Jurkat / Ara-c:

[0044] A. Cell culture: revive human acute T lymphoblastic leukemia Jurkat cells, suspend them in RPMI-1640 medium (Hyclone company) with 10% fetal bovine serum (Gibco company), at a temperature of 37 ℃, CO 2 Cultured in an incubator with a concentration of 5% and saturated humidity.

[0045] B. Screening culture conditions: In the pre-experimental study, it was found that the median inhibitory concentration IC50 of Ara-c intervening in Jurkat cells for 48h was 0.01μg / ml. In this experiment, 0.02μg / ml Ara-C was selected as the initial culture concentration.

[0046] C. Construction of drug-resistant cell lines: Jurkat cells were continuously cultured in complete medium containing 0.02μg / ml, the medium was changed every 2-3 days, and cell viability was observed and photographed; When stably proliferating under...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of biological medicines, and discloses a construction method of an acute T lymphocytic leukemia cytarabine drug-resistant cell strain. The construction method comprises the following steps: A, suspending leukemia cells Jurkat in a culture medium, and performing culturing in an incubator; B, continuously culturing the Jurkat cells in a complete culture medium containing 0.02 [mu]g / ml of Ara-C, and changing the liquid every 2-3 days; C, when the Jurkat cells can stably proliferate under action of the 0.02 [mu]g / ml of Ara-C, gradually increasing the concentration of the Ara-C, and repeatedly performing subculturing until the Jurkat cells stably survive under a condition that the concentration of Ara-C is 1 [mu]g / ml, so as to obtain the Jurkat / Ara-C-resistant cell strain, and detecting the drug resistance multiple; and D, continuously culturing the Jurkat / Ara-C cell strain for 1 month by using an Ara-C-free complete culture medium, and detectingthe drug resistance multiple again. The invention provides a new cell model for leukemia research.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a method for constructing an acute T lymphoblastic leukemia cytarabine-resistant cell line. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a malignant clonal disease characterized by abnormal proliferation of immature T or B lymphocytes, and is the most common malignant tumor in children. In China, ALL accounts for about 60% of childhood leukemias, and epidemiological surveys have found that its incidence is increasing dynamically. [0003] In recent years, with the optimization and adjustment of risk grouping and chemotherapy drug doses, the curative effect of children with ALL (especially T-type ALL) has been significantly improved. The study of the AALL0434 program of the International Children's Oncology Group found that children with T-ALL patients had a 5-year history of T-ALL. The event-free survival (EFS) rate has reached more than 80%. At present...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/09C12N5/078C12N5/02C12R1/91
CPCC12N5/0634C12N5/0694C12N2500/40
Inventor 刘文君覃祥刘静龙思利
Owner THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com